{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:14:19Z","timestamp":1791497659150,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Treatment of carbapenem-resistant <jats:italic>Acinetobacter baumannii<\/jats:italic> (CRAB) presents a growing clinical challenge. This study evaluated the in vitro efficacy of eravacycline and the potential synergistic activity of meropenem-vaborbactam in combination with either gentamicin or ceftazidime against carbapenemase-producing <jats:italic>Acinetobacter baumannii<\/jats:italic> isolates. A total of 25 CRAB isolates were collected from different clinical samples. Antimicrobial susceptibility was determined via disc diffusion. Meropenem was tested by both disc diffusion and gradient strips. Polymerase chain reaction (PCR) was used to screen these isolates for the carbapenemase genes <jats:italic>bla<\/jats:italic>\n            <jats:sub>\n              <jats:italic>OXA-51,<\/jats:italic>\n            <\/jats:sub>\n            <jats:italic> bla<\/jats:italic>\n            <jats:sub>\n              <jats:italic>OXA-23,<\/jats:italic>\n            <\/jats:sub>\n            <jats:italic> bla<\/jats:italic>\n            <jats:sub>\n              <jats:italic>IMP<\/jats:italic>\n            <\/jats:sub>\n            <jats:italic>, bla<\/jats:italic>\n            <jats:sub>\n              <jats:italic>VIM<\/jats:italic>\n            <\/jats:sub>\n            <jats:italic>, bla<\/jats:italic>\n            <jats:sub>\n              <jats:italic>OXA-48<\/jats:italic>\n            <\/jats:sub>\n            <jats:italic>, bla<\/jats:italic>\n            <jats:sub>\n              <jats:italic>NDM<\/jats:italic>\n            <\/jats:sub>\u00a0and\u00a0<jats:italic>bla<\/jats:italic>\n            <jats:sub>\n              <jats:italic>KPC<\/jats:italic>\n            <\/jats:sub>. Extensively drug-resistant (XDR) CRAB isolates were selected for evaluating colistin, eravacycline and the in vitro synergy of antimicrobial combinations via gradient strips for meropenem-vaborbactam, gentamicin, and ceftazidime. All CRAB isolates were sensitive to tigecycline and were either multidrug resistant or XDR. The minimum inhibitory concentrations (MIC50s and MIC90s) of meropenem were 32\u00a0\u03bcg\/mL and 256\u00a0\u03bcg\/mL, respectively. Among these genes, <jats:italic>bla<\/jats:italic>\n            <jats:sub>\n              <jats:italic>OXA-23<\/jats:italic>\n            <\/jats:sub> was the most prevalent gene. The MIC<jats:sub>50<\/jats:sub> and MIC<jats:sub>90<\/jats:sub> of colistin were 1 and 2\u00a0\u03bcg\/mL, respectively. The MIC<jats:sub>50<\/jats:sub> and MIC<jats:sub>90<\/jats:sub> of eravacycline were 0.125\u00a0\u03bcg\/mL and 0.5\u00a0\u03bcg\/mL, respectively. Meropenem-vaborbactam in combination with ceftazidime or gentamicin showed synergy in 45.5% and 36.4% of the XDR isolates and additivity\/indifference in 54.5% and 63.6% of them, respectively, with no antagonism. Our findings suggest that eravacycline, as well as combination therapies involving meropenem-vaborbactam with either gentamicin or ceftazidime, may offer promising therapeutic potential for CRAB infections pending further clinical evaluation. These agents demonstrated notable in vitro activity, including potential synergistic effects, particularly against isolates harboring carbapenemase enzymes.<\/jats:p>","DOI":"10.1038\/s41598-025-19642-y","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:43:25Z","timestamp":1759250605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii"],"prefix":"10.1038","volume":"15","author":[{"given":"Amira H.","family":"El-Ashry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mostafa","family":"Abdrabou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"El-Tantawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"El-Mahdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"3","key":"19642_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.18683\/germs.2019.1168","volume":"9","author":"H El El Hafa","year":"2019","unstructured":"El El Hafa, H. et al. Dissemination of carbapenem-resistant Acinetobacter baumannii strains carrying the blaGES, blaNDM and blaOXA23 in Morocco. Germs 9(3), 133\u2013141. https:\/\/doi.org\/10.18683\/germs.2019.1168 (2019).","journal-title":"Germs"},{"key":"19642_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13756-019-0611-6","volume":"8","author":"A Abouelfetouh","year":"2019","unstructured":"Abouelfetouh, A., Torky, A. S. & Aboulmagd, E. Phenotypic and genotypic characterization of carbapenem-resistant Acinetobacter baumannii isolates from Egypt. Antimicrob. Resist. Infect. Control 8, 185. https:\/\/doi.org\/10.1186\/s13756-019-0611-6 (2019).","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"19642_CR3","unstructured":"Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities. (2017). World Health Organization."},{"issue":"3","key":"19642_CR4","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1128\/CMR.00058-07","volume":"21","author":"AY Peleg","year":"2008","unstructured":"Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21(3), 538\u2013582. https:\/\/doi.org\/10.1128\/CMR.00058-07 (2008).","journal-title":"Clin. Microbiol. Rev."},{"issue":"6","key":"19642_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3390\/antibiotics13060506","volume":"13","author":"F Serapide","year":"2024","unstructured":"Serapide, F. et al. Antibiotic treatment of carbapenem-resistant Acinetobacter baumannii infections in view of the newly developed \u03b2-lactams: A narrative review of the existing evidence. Antibiotics 13(6), 506 (2024).","journal-title":"Antibiotics"},{"key":"19642_CR6","doi-asserted-by":"publisher","first-page":"1395260","DOI":"10.3389\/fcimb.2024.1395260","volume":"14","author":"S Zhang","year":"2024","unstructured":"Zhang, S., Di, L., Qi, Y., Qian, X. & Wang, S. Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Front. Cell. Infect. Microbiol. 14, 1395260. https:\/\/doi.org\/10.3389\/fcimb.2024.1395260 (2024).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"5","key":"19642_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel, G. G. et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76(5), 567\u2013588. https:\/\/doi.org\/10.1007\/s40265-016-0545-8 (2016).","journal-title":"Drugs"},{"issue":"6","key":"19642_CR8","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1128\/AAC.00436-16","volume":"60","author":"DM Livermore","year":"2016","unstructured":"Livermore, D. M., Mushtaq, S., Warner, M. & Woodford, N. In vitro activity of eravacycline against carbapenem-resistant enterobacteriaceae and Acinetobacter baumannii. Antimicrob. Agents Chemother. 60(6), 3840\u20133844. https:\/\/doi.org\/10.1128\/AAC.00436-16 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"19642_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/cid\/ciy576","volume":"68","author":"JM Pogue","year":"2019","unstructured":"Pogue, J. M., Bonomo, R. A. & Kaye, K. S. Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? Clinical and formulary considerations. Clin. Infect. Dis. Off. Pub. Infect. Dis. Soc. Am. 68(3), 519\u2013524. https:\/\/doi.org\/10.1093\/cid\/ciy576 (2019).","journal-title":"Clin. Infect. Dis. Off. Pub. Infect. Dis. Soc. Am."},{"issue":"5","key":"19642_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/antibiotics10050536","volume":"10","author":"P Gaibani","year":"2021","unstructured":"Gaibani, P. et al. Epidemiology of meropenem\/vaborbactam resistance in KPC-producing Klebsiella pneumoniae causing bloodstream infections in northern Italy, 2018. Antibiotics 10(5), 536. https:\/\/doi.org\/10.3390\/antibiotics10050536 (2021).","journal-title":"Antibiotics"},{"issue":"5","key":"19642_CR11","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/jac\/dky557","volume":"74","author":"P Gaibani","year":"2019","unstructured":"Gaibani, P., Ambretti, S., Viale, P. & Re, M. C. In vitro synergistic activity of meropenem\/vaborbactam in combination with ceftazidime\/avibactam against KPC-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 74(5), 1457\u20131459. https:\/\/doi.org\/10.1093\/jac\/dky557 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"19642_CR12","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2147\/IDR.S257851","volume":"13","author":"S Raut","year":"2020","unstructured":"Raut, S. et al. Trend and characteristics of Acinetobacter baumannii infections in patients attending universal college of medical sciences, Bhairahawa, western Nepal: A longitudinal study of 2018. Infect. Drug Resist. 13, 1631\u20131641. https:\/\/doi.org\/10.2147\/IDR.S257851 (2020).","journal-title":"Infect. Drug Resist."},{"key":"19642_CR13","unstructured":"CLSI (Clinical and Laboratory Standards Institute) (2023): Performance standards for antimicrobial susceptibility testing. 33rd ed. CLSI supplement M100.Wayne."},{"key":"19642_CR14","unstructured":"US Food and Drug Administration. Antibacterial susceptibility test interpretative criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/eravacycline-injection-products (accessed 27 July 2024)."},{"issue":"3","key":"19642_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. Off. Pub. Eu. Soc. Clin. Microbiol. Infect. Dis. 18(3), 268\u2013281. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x (2012).","journal-title":"Clin. Microbiol. Infect. Off. Pub. Eu. Soc. Clin. Microbiol. Infect. Dis."},{"key":"19642_CR16","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 14.0. 2024. http:\/\/www.eucast.org"},{"issue":"4","key":"19642_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ijantimicag.2006.01.004","volume":"27","author":"N Woodford","year":"2006","unstructured":"Woodford, N. et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27(4), 351\u2013353. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.01.004 (2006).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"19642_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","volume":"70","author":"L Poirel","year":"2011","unstructured":"Poirel, L., Walsh, T. R., Cuvillier, V. & Nordmann, P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn. Microbiol. Infect. Dis. 70(1), 119\u2013123. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.12.002 (2011).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"4","key":"19642_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/jpy.13175","volume":"57","author":"SK Shin","year":"2021","unstructured":"Shin, S. K., Lee, Y., Kwon, H., Rhee, J. S. & Kim, J. K. Validation of direct boiling method for simple and efficient genomic DNA extraction and PCR-based macroalgal species determination. J. Phycol. 57(4), 1368\u20131372. https:\/\/doi.org\/10.1111\/jpy.13175 (2021).","journal-title":"J. Phycol."},{"key":"19642_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fcimb.2017.00209","volume":"7","author":"MAH Soudeiha","year":"2017","unstructured":"Soudeiha, M. A. H., Dahdouh, E. A., Azar, E., Sarkis, D. K. & Daoud, Z. In vitro evaluation of the colistin-carbapenem combination in clinical isolates of A. baumannii using the checkerboard, etest, and time-kill curve techniques. Front. Cell. Infect. Microbiol. 7, 209. https:\/\/doi.org\/10.3389\/fcimb.2017.00209 (2017).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"2","key":"19642_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3343\/alm.2016.36.2.138","volume":"36","author":"H Lee","year":"2016","unstructured":"Lee, H. et al. In vitro synergistic effects of antimicrobial combinations on extensively drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates. Ann. Lab. Med. 36(2), 138\u2013144. https:\/\/doi.org\/10.3343\/alm.2016.36.2.138 (2016).","journal-title":"Ann. Lab. Med."},{"key":"19642_CR22","unstructured":"IBM Corp. (2020). IBM SPSS Statistics for Windows, Version 25.0. Armonk,\u00a0NY:\u00a0IBM Corp."},{"issue":"2","key":"19642_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","volume":"11","author":"C Bartal","year":"2022","unstructured":"Bartal, C., Rolston, K. V. I. & Nesher, L. Carbapenem-resistant Acinetobacter baumannii: Colonization, infection and current treatment options. Infect. Dis. Ther. 11(2), 683\u2013694. https:\/\/doi.org\/10.1007\/s40121-022-00597-w (2022).","journal-title":"Infect. Dis. Ther."},{"issue":"6","key":"19642_CR24","doi-asserted-by":"publisher","first-page":"e0226023","DOI":"10.1128\/mbio.02260-23","volume":"14","author":"C M\u00fcller","year":"2023","unstructured":"M\u00fcller, C. et al. A global view on carbapenem-resistant Acinetobacter baumannii. MBio 14(6), e0226023. https:\/\/doi.org\/10.1128\/mbio.02260-23 (2023).","journal-title":"MBio"},{"issue":"7","key":"19642_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/antibiotics11070835","volume":"11","author":"SA Al-Sheboul","year":"2022","unstructured":"Al-Sheboul, S. A. et al. Molecular characterization of carbapenem-resistant Acinetobacter baumannii isolated from intensive care unit patients in Jordanian hospitals. Antibiotics 11(7), 835. https:\/\/doi.org\/10.3390\/antibiotics11070835 (2022).","journal-title":"Antibiotics"},{"issue":"1","key":"19642_CR26","first-page":"14","volume":"8","author":"VU Nwadike","year":"2014","unstructured":"Nwadike, V. U., Ojide, C. K. & Kalu, E. I. Multidrug resistant acinetobacter infection and their antimicrobial susceptibility pattern in a Nigerian tertiary hospital ICU. Afr. J. Infect. Dis. 8(1), 14\u201318 (2014).","journal-title":"Afr. J. Infect. Dis."},{"key":"19642_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.11604\/pamj.2019.33.146.17220","volume":"33","author":"VM Musyoki","year":"2019","unstructured":"Musyoki, V. M. et al. Antimicrobial susceptibility pattern of Acinetobacter isolates from patients in Kenyatta National Hospital, Nairobi, Kenya. Pan Afr. Med. J. 33, 146. https:\/\/doi.org\/10.11604\/pamj.2019.33.146.17220 (2019).","journal-title":"Pan Afr. Med. J."},{"key":"19642_CR28","doi-asserted-by":"publisher","first-page":"3925868","DOI":"10.1155\/2017\/3925868","volume":"2017","author":"NM Alkasaby","year":"2017","unstructured":"Alkasaby, N. M. & El Sayed Zaki, M. Molecular study of Acinetobacter baumannii isolates for metallo-\u03b2-lactamases and extended-spectrum-\u03b2-lactamases genes in intensive care unit, Mansoura university hospital, Egypt. Int. J. Microbiol. 2017, 3925868. https:\/\/doi.org\/10.1155\/2017\/3925868 (2017).","journal-title":"Int. J. Microbiol."},{"issue":"1","key":"19642_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12941-022-00536-0","volume":"21","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Insight into carbapenem resistance and virulence of Acinetobacter baumannii from a children\u2019s medical center in eastern China. Ann. Clin. Microbiol. Antimicrob. 21(1), 47. https:\/\/doi.org\/10.1186\/s12941-022-00536-0 (2022).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"issue":"2","key":"19642_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3947\/ic.2023.0091","volume":"56","author":"KH Lee","year":"2024","unstructured":"Lee, K. H. et al. Carbapenem-resistant Acinetobacter baumannii outbreak in a COVID-19 isolation ward and successful outbreak control with infection control measures. Infect. Chemother. 56(2), 222\u2013229. https:\/\/doi.org\/10.3947\/ic.2023.0091 (2024).","journal-title":"Infect. Chemother."},{"issue":"7","key":"19642_CR31","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/antibiotics12071198","volume":"12","author":"N Al-Rashed","year":"2023","unstructured":"Al-Rashed, N. et al. Prevalence of carbapenemases in carbapenem-resistant Acinetobacter baumannii isolates from the Kingdom of Bahrain. Antibiotics 12(7), 1198. https:\/\/doi.org\/10.3390\/antibiotics12071198 (2023).","journal-title":"Antibiotics"},{"issue":"6","key":"19642_CR32","doi-asserted-by":"publisher","first-page":"e0251508","DOI":"10.1371\/journal.pone.0251508","volume":"16","author":"RM Hassan","year":"2021","unstructured":"Hassan, R. M., Salem, S. T., Hassan, S. I. M., Hegab, A. S. & Elkholy, Y. S. Molecular characterization of carbapenem-resistant Acinetobacter baumannii clinical isolates from Egyptian patients. PLoS ONE 16(6), e0251508. https:\/\/doi.org\/10.1371\/journal.pone.0251508 (2021).","journal-title":"PLoS ONE"},{"issue":"3","key":"19642_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/sur.2024.210","volume":"26","author":"NY Sahlol","year":"2025","unstructured":"Sahlol, N. Y. et al. Molecular identification of OXA carbapenemase-encoding genes in Acinetobacter baumannii isolated from patients in critical care in Egypt. Surg. Infect. 26(3), 158\u2013163. https:\/\/doi.org\/10.1089\/sur.2024.210 (2025).","journal-title":"Surg. Infect."},{"key":"19642_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijid.2013.12.004","volume":"22","author":"MH Al-Agamy","year":"2014","unstructured":"Al-Agamy, M. H., Khalaf, N. G., Tawfick, M. M., Shibl, A. M. & El Kholy, A. Molecular characterization of carbapenem-insensitive Acinetobacter baumannii in Egypt. Int. J. Infect. Dis. 22, 49\u201354. https:\/\/doi.org\/10.1016\/j.ijid.2013.12.004 (2014).","journal-title":"Int. J. Infect. Dis."},{"issue":"3","key":"19642_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1089\/mdr.2017.0057","volume":"24","author":"AMS El Bannah","year":"2018","unstructured":"El Bannah, A. M. S., Nawar, N. N., Hassan, R. M. M. & Salem, S. T. B. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in a tertiary care hospital in Egypt: Clonal spread of blaOXA-23. Microb. Drug Resist. 24(3), 269\u2013277. https:\/\/doi.org\/10.1089\/mdr.2017.0057 (2018).","journal-title":"Microb. Drug Resist."},{"issue":"5","key":"19642_CR36","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3855\/jidc.15902","volume":"16","author":"D Anggraini","year":"2022","unstructured":"Anggraini, D., Kemal, R. A., Hadi, U. & Kuntaman, K. The susceptibility pattern and distribution of blaOXA-23 genes of clinical isolate Acinetobacter baumannii in a tertiary hospital, Indonesia. J. Infect. Dev. Ctries. 16(5), 821\u2013826. https:\/\/doi.org\/10.3855\/jidc.15902 (2022).","journal-title":"J. Infect. Dev. Ctries."},{"key":"19642_CR37","doi-asserted-by":"publisher","first-page":"1068840","DOI":"10.3389\/fcimb.2022.1068840","volume":"12","author":"S Sharma","year":"2023","unstructured":"Sharma, S., Banerjee, T., Yadav, G. & Kumar, A. Susceptibility profile of blaOXA-23 and metallo-\u03b2-lactamases coharbouring isolates of carbapenem resistant Acinetobacter baumannii (CRAB) against standard drugs and combinations. Front. Cell. Infect. Microbiol. 12, 1068840. https:\/\/doi.org\/10.3389\/fcimb.2022.1068840 (2023).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"19642_CR38","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.3892\/mmr.2016.5538","volume":"14","author":"SZ Xiao","year":"2016","unstructured":"Xiao, S. Z. et al. Resistant mechanisms and molecular epidemiology of imipenem-resistant Acinetobacter baumannii. Mol. Med. Rep. 14(3), 2483\u20132488. https:\/\/doi.org\/10.3892\/mmr.2016.5538 (2016).","journal-title":"Mol. Med. Rep."},{"key":"19642_CR39","doi-asserted-by":"publisher","first-page":"6203","DOI":"10.2147\/IDR.S385411","volume":"15","author":"R Shrief","year":"2022","unstructured":"Shrief, R., El-Ashry, A. H., Mahmoud, R. & El-Mahdy, R. Effect of colistin, fosfomycin and meropenem\/vaborbactam on carbapenem-resistant enterobacterales in Egypt: A cross-sectional study. Infect. Drug Resist. 15, 6203\u20136214. https:\/\/doi.org\/10.2147\/IDR.S385411 (2022).","journal-title":"Infect. Drug Resist."},{"issue":"4","key":"19642_CR40","first-page":"506","volume":"55","author":"YM Hu","year":"2021","unstructured":"Hu, Y. M. & Li, J. Clinical application of mCIM and Ecim combined detection of carbapenemase-producing Enterobacteriaceae. Zhonghua yu Fang yi xue za zhi [Chin. J. Prevent. Med.] 55(4), 506\u2013511 (2021).","journal-title":"Zhonghua yu Fang yi xue za zhi [Chin. J. Prevent. Med.]"},{"issue":"2","key":"19642_CR41","doi-asserted-by":"publisher","first-page":"001639","DOI":"10.1099\/jmm.0.001639","volume":"72","author":"RM Abdel Halim","year":"2023","unstructured":"Abdel Halim, R. M., Saber, S. M. & Fahim, N. A. E. Evaluation of synergistic activity of antibiotic combinations in extensive drug-resistant Acinetobacter species using checkerboard assay. J. Med. Microbiol. 72(2), 001639. https:\/\/doi.org\/10.1099\/jmm.0.001639 (2023).","journal-title":"J. Med. Microbiol."},{"issue":"3","key":"19642_CR42","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah, M. et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob. Agents Chemother. 59(3), 1802\u20131805. https:\/\/doi.org\/10.1128\/AAC.04809-14 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"19642_CR43","doi-asserted-by":"publisher","first-page":"e01699","DOI":"10.1128\/AAC.01699-19","volume":"64","author":"I Morrissey","year":"2020","unstructured":"Morrissey, I. et al. In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob. Agents Chemother. 64(3), e01699-e1719. https:\/\/doi.org\/10.1128\/AAC.01699-19 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"19642_CR44","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/antibiotics11101298","volume":"11","author":"MS Deolankar","year":"2022","unstructured":"Deolankar, M. S. et al. Evaluating the efficacy of eravacycline and omadacycline against extensively drug-resistant Acinetobacter baumannii patient isolates. Antibiotics 11(10), 1298. https:\/\/doi.org\/10.3390\/antibiotics11101298 (2022).","journal-title":"Antibiotics"},{"key":"19642_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jgar.2022.05.020","volume":"30","author":"Y Li","year":"2022","unstructured":"Li, Y., Cui, L., Xue, F., Wang, Q. & Zheng, B. Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. J. Glob. Antimicrob. Resist. 30, 56\u201359. https:\/\/doi.org\/10.1016\/j.jgar.2022.05.020 (2022).","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"11","key":"19642_CR46","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/antibiotics12111612","volume":"12","author":"A Duda-Madej","year":"2023","unstructured":"Duda-Madej, A., Viscardi, S. & Topola, E. Meropenem\/vaborbactam: \u03b2-Lactam\/\u03b2-lactamase inhibitor combination, the future in eradicating multidrug resistance. Antibiotics 12(11), 1612. https:\/\/doi.org\/10.3390\/antibiotics12111612 (2023).","journal-title":"Antibiotics"},{"issue":"2","key":"19642_CR47","first-page":"752","volume":"6","author":"DS ElFeky","year":"2024","unstructured":"ElFeky, D. S., Awad, A. R., Hamed, R. M. R., Baddour, M. M. & Mowafy, H. L. In vitro activity of ceftazidime-avibactam and meropenem-vaborbactam against carbapenem-resistant Enterobacterales in Egyptian Hospitals: A challenge for clinical practice. Microb. Infect. Dis. 6(2), 752\u2013761 (2024).","journal-title":"Microb. Infect. Dis."},{"issue":"3","key":"19642_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/1120009X.2022.2095156","volume":"35","author":"M Abd El-Aziz Gadallah","year":"2023","unstructured":"Abd El-Aziz Gadallah, M., El-Sayed, W. M., Hussien, M. Z., Elheniedy, M. A. & Maxwell, S. Y. In vitro activity of plazomicin, meropenem-vaborbactam, and omadacycline against carbapenem-resistant gram-negative isolates in Egypt. J. Chemother. 35(3), 205\u2013218. https:\/\/doi.org\/10.1080\/1120009X.2022.2095156 (2023).","journal-title":"J. Chemother."},{"issue":"8","key":"19642_CR49","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/antibiotics10081023","volume":"10","author":"P Terbtothakun","year":"2021","unstructured":"Terbtothakun, P., Nwabor, O. F., Siriyong, T., Voravuthikunchai, S. P. & Chusri, S. Synergistic antibacterial effects of meropenem in combination with aminoglycosides against carbapenem-resistant Escherichia coli harboring blaNDM-1 and blaNDM-5. Antibiotics 10(8), 1023. https:\/\/doi.org\/10.3390\/antibiotics10081023 (2021).","journal-title":"Antibiotics"},{"key":"19642_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.14649","volume":"1496","author":"M Zhu","year":"2021","unstructured":"Zhu, M., Tse, M. W., Weller, J., Chen, J. & Blainey, P. C. The future of antibiotics begins with discovering new combinations. Ann. N. Y. Acad. Sci. 1496, 82\u201396. https:\/\/doi.org\/10.1111\/nyas.14649 (2021).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"19642_CR51","doi-asserted-by":"publisher","first-page":"dlad113","DOI":"10.1093\/jacamr\/dlad113","volume":"5","author":"TM Rogers","year":"2023","unstructured":"Rogers, T. M. et al. Mutations in ompK36 differentially impact in vitro synergy of meropenem\/vaborbactam and ceftazidime\/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae. JAC-Antimicrob. Resist. 5, dlad113. https:\/\/doi.org\/10.1093\/jacamr\/dlad113 (2023).","journal-title":"JAC-Antimicrob. Resist."},{"issue":"4","key":"19642_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/antibiotics13040331","volume":"13","author":"LF Rezzonico","year":"2024","unstructured":"Rezzonico, L. F. et al. Meropenem-vaborbactam for the treatment of post-neurosurgical meningitis caused by KPC producer Klebsiella pneumoniae: A case report and review of the literature. Antibiotics 13(4), 331. https:\/\/doi.org\/10.3390\/antibiotics13040331 (2024).","journal-title":"Antibiotics"},{"issue":"12","key":"19642_CR53","doi-asserted-by":"publisher","first-page":"e00722","DOI":"10.1128\/AAC.00722-17","volume":"61","author":"R Yadav","year":"2017","unstructured":"Yadav, R. et al. Aminoglycoside concentrations required for synergy with carbapenems against Pseudomonas aeruginosa determined via mechanistic studies and modeling. Antimicrob. Agents Chemother. 61(12), e00722-e817. https:\/\/doi.org\/10.1128\/AAC.00722-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"19642_CR54","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.2147\/IDR.S408228","volume":"16","author":"J Kuai","year":"2023","unstructured":"Kuai, J. et al. In vitro synergistic activity of ceftazidime-avibactam in combination with aztreonam or meropenem against clinical Enterobacterales producing blaKPC or blaNDM. Infect. Drug Resist.ance 16, 3171\u20133182. https:\/\/doi.org\/10.2147\/IDR.S408228 (2023).","journal-title":"Infect. Drug Resist.ance"},{"key":"19642_CR55","doi-asserted-by":"crossref","unstructured":"Essa, S. A., Helaly, N. A., & Baz, A. S. (2025). Evaluation of ceftazidime\/avibactam alone and in combination with amikacin, colistin and meropenem against carbapenemase-producing Klebsiella pneumoniae. Microb. Infect. Dis.","DOI":"10.21608\/mid.2025.334215.2332"},{"key":"19642_CR56","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/IDR.S292431","volume":"14","author":"E Liu","year":"2021","unstructured":"Liu, E. et al. In vitro and in vivo effect of antimicrobial agent combinations against carbapenem-resistant Klebsiella pneumoniae with different resistance mechanisms in China. Infect. Drug Resist. 14, 917\u2013928. https:\/\/doi.org\/10.2147\/IDR.S292431 (2021).","journal-title":"Infect. Drug Resist."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19642-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T03:11:00Z","timestamp":1759633860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19642-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19642"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19642-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Institutional Review Board (IRB), Mansoura Faculty of Medicine, Egypt, code number R.25.05.3186, approved the revision of patients\u2019 medical records and collection of bacterial isolates with informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"34109"}}